Type 2 Diabetes Mellitus Research and Development Services

Type 2 Diabetes Mellitus Research and Development Services

Type 2 diabetes mellitus (T2DM), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin.

As a dedicated CRO company, Ace Therapeutics provides a full range of T2DM-related services to leading pharmaceutical, biotechnology, agrochemical, governmentand academic organisations around the world to help you make progress on the discovery of new or modified medications, insulin alternatives or treatments.

Pathogenesis of T2DM

T2DM is associated with insulin resistance and islet β-cell dysfunction. It is caused by the relatively insufficient insulin related to obesity and the tissue is not sensitive to insulin (insulin resistance). The development of T2DM is a continuum from a state of impaired glucose tolerance (IGT), where patients exhibit a very high level of IR and have lost an estimated 80% of their β-cell function to T2DM.

T2DM is characterized by hyperinsulinemia, insulin resistance, and pancreatic beta-cell failure (up to 50% apoptosis). Incretin effects, changes in the colon and its microbiota, immune dysregulation, and inflammation have now emerged as important pathophysiological factors. The mechanisms of microvascular and macrovascular complications caused by hyperglycemia are endothelial dysfunction, advanced glycation end product formation, hypercoagulable state, increased platelet reactivity, high expression of sodium-glucose cotransporter-2 (SGLT-2), These are all targets for the treatment of diabetes.

Pathogenesis of T2DM (Ke, Calvin et al., 2022)Pathogenesis of T2DM (Ke, Calvin et al., 2022)

Therapy of T2DM

  • Oral Hypoglycemic Therapy

The hyperglycemia of T2DM is often inadequately controlled, hence the need for a wider selection of glucose-lowering treatments. GLP-1R agonists and some oral antidiabetics such as insulin analogs can improve glycaemia control and reduce weight in patients with T2DM, making them an effective pharmacological agent.

  • Antibody Therapy

Monoclonal antibody therapy is a form of immunotherapy that uses monoclonal antibodies to bind nonspecifically to certain cells or proteins. Insulin acts by binding to the insulin receptor (INSR) on the cell surface, a process that activates cell signaling. Antibodies can activate the INSR and block insulin binding, causing severe insulin resistance and diabetes.

Biomarkers of T2DM

A biomarker is a biomolecule state that can be used for the prognosis, diagnosis and follow-up of the pathological state or the severity of a disease. The development of T2DM is a multifactorial and polygenic process, and its pathogenesis is complex. In addition, lipid metabolism, glucose metabolism and other metabolic abnormalities are closely related to the occurrence and development of T2DM. Accurate prediction and identification using these biomarkers will be useful for the development of therapies of T2DM.

Our Services

Diabetes is a field worthy of in-depth research, and experts and scholars in the field of diabetes have never stopped pursuing technological innovation. Ace Therapeutics provides research programs and technical services from pathology to preclinical. Our services include but not limited to the followings.

Providing research services to study the genes, biochemical pathways related to diabetes at the molecular and cellular levels, and carry out integration and systematic analysis.

Providing modeling service for T2DM study for understanding the mechanism and development of T2DM, as well as developing therapy and diagnosis for T2DM.

Providing a full set of services including therapeutic biomolecular drug development services for T2DM.

Providing a set of services including genetic biomarkers development, metabolomics and circulating biomarkers development, etc.

We provide effective diagnostics development service based on different types of markers, that can help clients complete their disease model analysis more efficiently and help accelerate therapy development of T2DM.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualitysHigh Quality

Professional TeamProfessional Team

With many years of experience in translational medicine research and preclinical research. Ace Therapeutics can provide our clients with treatment development solutions, and accelerate the process of treatment development and drug discovery. We guarantee to deliver our products and results on time. Please feel free to contact us.


  1. Shah, N.; et al. Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Therapeutic Advances in Endocrinology and Metabolism. 2021, 12, 20420188211042145.
  2. Ke, Calvin et al. Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nature reviews. Endocrinology vol. 18,7 (2022): 413-432.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.